Share on StockTwits

Allergan (NYSE:AGN)‘s stock had its “hold” rating reaffirmed by analysts at Jefferies Group in a research report issued to clients and investors on Tuesday, American Banking & Market News reports. They currently have a $139.00 price target on the stock. Jefferies Group’s price objective suggests a potential downside of 16.08% from the stock’s previous close.

Allergan (NYSE:AGN) traded down 0.22% during mid-day trading on Tuesday, hitting $165.63. The stock had a trading volume of 4,818,510 shares. Allergan has a 52 week low of $81.33 and a 52 week high of $169.29. The stock’s 50-day moving average is $132.8 and its 200-day moving average is $113.8. The company has a market cap of $49.435 billion and a P/E ratio of 50.92.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $1.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company’s revenue for the quarter was up 14.4% on a year-over-year basis. On average, analysts predict that Allergan will post $5.48 earnings per share for the current fiscal year.

In other Allergan news, EVP Scott Sherman sold 14,500 shares of the stock on the open market in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $155.82, for a total transaction of $2,259,390.00. Following the transaction, the executive vice president now directly owns 8,223 shares of the company’s stock, valued at approximately $1,281,308. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Several other analysts have also recently commented on the stock. Analysts at Sterne Agee raised their price target on shares of Allergan to $185.00 in a research note on Monday. Separately, analysts at Stifel Nicolaus downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $125.00 price target on the stock. Finally, analysts at Edward Jones downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, April 23rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $139.13.

Allergan, Inc is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.